These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36856926)

  • 1. Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates.
    Graham DY
    Dig Dis Sci; 2023 May; 68(5):1691-1697. PubMed ID: 36856926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance.
    Graham DY; Lu H; Shiotani A
    J Gastroenterol Hepatol; 2021 May; 36(5):1159-1163. PubMed ID: 32918832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
    Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
    Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
    Ratana-Amornpin S; Sanglutong L; Eiamsitrakoon T; Siramolpiwat S; Graham DY; Mahachai V
    Helicobacter; 2023 Dec; 28(6):e13019. PubMed ID: 37723133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
    Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
    Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
    Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vonoprazan: A Review in Helicobacter pylori Infection.
    Shirley M
    Drugs; 2024 Mar; 84(3):319-327. PubMed ID: 38388872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.
    Matsumoto H; Shiotani A; Katsumata R; Fujita M; Nakato R; Murao T; Ishii M; Kamada T; Haruma K; Graham DY
    Dig Dis Sci; 2016 Nov; 61(11):3215-3220. PubMed ID: 27659671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
    J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
    Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
    Sakurai Y; Shiino M; Okamoto H; Nishimura A; Nakamura K; Hasegawa S
    Adv Ther; 2016 Sep; 33(9):1519-35. PubMed ID: 27432383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
    Horie R; Handa O; Ando T; Ose T; Murakami T; Suzuki N; Sendo R; Imamoto E; Itoh Y
    Helicobacter; 2020 Aug; 25(4):e12698. PubMed ID: 32368846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of
    Liu L; Nahata MC
    Ann Pharmacother; 2023 Oct; 57(10):1185-1197. PubMed ID: 36688309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
    Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
    Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
    Inokuchi K; Mori H; Matsuzaki J; Hirata K; Harada Y; Saito Y; Suzuki H; Kanai T; Masaoka T
    Helicobacter; 2022 Aug; 27(4):e12900. PubMed ID: 35644041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
    Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
    Du RC; Ouyang YB; Lu NH; Hu Y
    Helicobacter; 2023 Oct; 28(5):e13012. PubMed ID: 37515414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
    Yunusa I; Love BL
    Am J Gastroenterol; 2023 Apr; 118(4):635-644. PubMed ID: 36693030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.